Key Takeaways: Akeso swung to an annual profit of 1.94 billion yuan, boosted by licensing income of 2.92 billion yuan The next highly anticipated product in the firm’s drug pipeline is ivonescimab, the first PD-1/VEGF bispecific antibody to enter Phase III clinical trials By Molly Wen

Related Keywords

Hong Kong , United States , Tianqing , Zhejiang , China , Canada , Japan , Chinese , Molly Wen , Akeso Inc , Chia Tai Tianqing Pharmaceutical Group , Citibank , Henlius Biotech ,